A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 47/48 (2006.01) A61K 38/19 (2006.01) A61P 7/00 (2006.01) C12N 5/071 (2010.01) C07K 17/08 (2006.01) C07K 17/10 (2006.01)
Patent
CA 2682897
The present invention provides a glycopegylated G-CSF that is therapeutically active and which has pharmacokinetic parameters and properties that are improved relative to an identical, or closely analogous, G-CSF peptide that is not glycopegylated. Furthermore, the invention provides methods for mobilizing hematopoiesis in a subject, particularly a subject who has received or will receive radiation or chemotherapy treatment. The methods and compositions of the invention can further be used to prevent, alleviate and treat the myelosuppressive effects such therapies.
La présente invention concerne un facteur G-CSF glycopégylé qui est thérapeutiquement actif et qui présente des paramètres et des propriétés pharmacocinétiques qui sont améliorées relativement à un peptide G-CSF identique, ou étroitement analogue, qui n'est pas glycopégylé. En outre, l'invention concerne des méthodes de mobilisation de l'hématopoïèse chez un sujet, en particulier un sujet qui a reçu ou va recevoir un traitement par irradiation ou un traitement chimiothérapeutique. Les méthodes et compositions de l'invention peuvent en outre être utilisées pour prévenir, soulager et traiter les effets myélosuppresseurs de tels traitements.
Lubenau Heinz
Zopf David A.
Biogenerix Ag
Gowling Lafleur Henderson Llp
LandOfFree
Methods of treatment using glycopegylated g-csf does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treatment using glycopegylated g-csf, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treatment using glycopegylated g-csf will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1383940